In the current study, treatment by the combination of RU.521 and EGFR inhibitors (afatinib or gefitinib) on two independent PDTOs supports the tumor-suppressing activity of co-inhibition of the cGAS-STING and EGFR pathways. Here, CGAS is linked to neoplasm.